Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline whole-exome sequencing identifies CTNND1 as a candidate gene for hereditary gastric cancer in a large Brazilian cohort.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same author

Neurosurgeons Are Essential in the Interdisciplinary Care of Patients With Brain Metastasis.

Neurosurgery·2026
Same author

Validation of Paw Skin Hyperspectral Imaging for Assessing Neuropathic Pain Severity in a Chronic Constriction Injury Model.

International journal of molecular sciences·2026
Same author

Beyond the naked eye: a systematic review on the current state of radiomics approaches to the vestibular schwannoma.

Journal of neuro-oncology·2026
Same author

Correction: Caloric Restriction Attenuated Nerve Damages Mediated Through SIRT-1-a Study Using Nerve Crush Injury Model in Rats.

Molecular neurobiology·2026
Same author

Radiotherapeutic management of metastatic brain disease: a two-decade meta-analysis of tumor control and neurocognitive outcomes with SRS alone versus SRS plus WBRT.

Journal of neuro-oncology·2026

Related Experiment Video

Updated: May 23, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Gamma knife radiosurgery for resectable brain metastasis.

Zhiyuan Xu1, Mohamed Elsharkawy, David Schlesinger

  • 1Department of Neurological Surgery, University of Virginia, Charlottesville, VA.

World Neurosurgery
|April 10, 2012
PubMed
Summary

Gamma Knife Radiosurgery (GKS) effectively treats non-small cell lung cancer (NSCLC) brain metastases near the brain surface. This treatment offers good tumor control and a low need for subsequent surgery.

Keywords:
Brain metastasisGKSGamma knife radiosurgeryKPSKarnofsky performance scoreMRMagnetic resonanceNSCLCNon–small cell lung cancerRPARecursive partitioning analysisResectableSRSStereotactic radiosurgeryWBRTWhole brain radiation therapy

More Related Videos

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Related Experiment Videos

Last Updated: May 23, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Area of Science:

  • Neurosurgery
  • Radiation Oncology
  • Oncology

Background:

  • Superficial brain metastases are typically treated with surgical resection.
  • Gamma Knife Radiosurgery (GKS) is evaluated for resectable non-small cell lung cancer (NSCLC) brain metastases within 3 cm of the cortical surface.

Purpose of the Study:

  • To evaluate the efficacy of GKS for resectable NSCLC brain metastases.
  • To assess survival, tumor control, and the need for craniotomy after GKS in this patient subgroup.

Main Methods:

  • Retrospective analysis of 64 patients with 111 NSCLC brain metastases treated between 1999-2009.
  • Inclusion criteria: 3 or fewer resectable metastases (<3 cm from cortical surface).
  • Evaluation of survival, local tumor control, and post-GKS craniotomy rates.

Main Results:

  • Mean overall survival after GKS was 13.5 months (median 8 months).
  • Actuarial local tumor control rate was 84% at 6 months.
  • Only 3% of patients required craniotomy for progressive disease after GKS.

Conclusions:

  • GKS is an effective treatment for patients with 3 or fewer resectable NSCLC brain metastases.
  • The rate of subsequent craniotomy after GKS for these tumors is minimal.